Abstract
5050Background: R223 and ENZA are standard of care agents in the treatment of patients (pts) with mCRPC. The combination of R223 and ENZA is of interest due to differing modes of action and non-ove...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have